Our client SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan …
We are very proud of our client, eyeSight Mobile Technologies, for closing a $20,000,000 strategic transaction with Kuang-Chi Science, and …
Katzenell Dimant represents Multiphy Ltd. in an $8.5 million financing round led by strategic partners and VCs. Read the press …
Katzenell Dimant represents Kitov Pharmaceuticals Holdings Ltd. in publishing a prospectus for public issuance of rights to purchase its securities and registration …
Katzenell Dimant represents the seller of Marmar Media Ltd. shares in a transaction for sale of a majority of the shares …
Katzenell Dimant represents Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE:KTOV) in several shelf offerings of its securities to the public. Kitov Pharmaceuticals is an …
Katzenell Dimant represents SteadyMed Ltd. in its Nasdaq IPO: on March 25, 2015, the company announced the closing of its …
KATZENELL DIMANT represents Technoplus Ventures Ltd. in publishing a shelf prospectus for public offering of its securities, and in registration of …
Katzenell Dimant represents Nextgen Biomed Ltd. (TLV: NXGN) in several shelf offerings of its securities to the public. Nextgen-Biomed is …